These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 9160821

  • 1. Impact of long-term naltrexone treatment on growth hormone and insulin secretion in hyperandrogenic and normal obese patients.
    Villa P, Fulghesu AM, De Marinis L, Valle D, Mancini A, Pavone V, Caruso A, Lanzone A.
    Metabolism; 1997 May; 46(5):538-43. PubMed ID: 9160821
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism.
    Villa P, Valle D, Mancini A, De Marinis L, Pavone V, Fulghesu AM, Mancuso S, Lanzone A.
    Fertil Steril; 1999 Jan; 71(1):115-21. PubMed ID: 9935127
    [Abstract] [Full Text] [Related]

  • 4. Effect of the opioid blockade on the feeding-induced growth hormone response to growth hormone-releasing hormone in women with polycystic ovary syndrome.
    Guido M, Romualdi D, Mancini A, Lattanzi F, Villa P, Barini A, Lanzone A, De Marinis L.
    Fertil Steril; 2002 Nov; 78(5):994-1000. PubMed ID: 12413983
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion.
    Lanzone A, Fulghesu AM, Cucinelli F, Ciampelli M, Caruso A, Mancuso S.
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3501-6. PubMed ID: 8530590
    [Abstract] [Full Text] [Related]

  • 8. Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome.
    Guido M, Pavone V, Ciampelli M, Murgia F, Fulghesu AM, Apa R, Caruso A, Mancuso S, Lanzone A.
    J Clin Endocrinol Metab; 1998 May; 83(5):1742-5. PubMed ID: 9589685
    [Abstract] [Full Text] [Related]

  • 9. Effect of feeding on growth hormone response to growth hormone-releasing hormone in polycystic ovarian syndrome: relation with body weight and hyperinsulinism.
    Villa P, Soranna L, Mancini A, De Marinis L, Valle D, Mancuso S, Lanzone A.
    Hum Reprod; 2001 Mar; 16(3):430-4. PubMed ID: 11228207
    [Abstract] [Full Text] [Related]

  • 10. GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.
    Orio F, Palomba S, Colao A, Russo T, Dentico C, Tauchmanovà L, Savastano S, Nappi C, Sultan C, Zullo F, Lombardi G.
    J Endocrinol Invest; 2003 Feb; 26(2):117-22. PubMed ID: 12739737
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Growth-hormone response to combined stimulation with GHRH plus GH-releasing peptide-6 in obese patients with polycystic ovary syndrome before and after short-term fasting.
    Micić D, Sumarac-Dumanović M, Macut Dj, Kendereski A, Zoric S, Popović V, Cvijović G, Dieguez C, Casanueva FF.
    J Endocrinol Invest; 2003 Apr; 26(4):333-40. PubMed ID: 12841541
    [Abstract] [Full Text] [Related]

  • 13. The inhibitory effect of glucose on growth hormone secretion is lost in obesity but not in hypertension.
    Limone P, Oleandri SE, Ajmone Catt P, Grottoli S, Frangioni C, Avogadri E, Perrin M, Valetto MR, Maccario M.
    J Endocrinol Invest; 1997 Nov; 20(10):616-20. PubMed ID: 9438920
    [Abstract] [Full Text] [Related]

  • 14. Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome.
    Ciampelli M, Muzj G, Leoni F, Romualdi D, Belosi C, Cento RM, Lanzone A.
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5324-9. PubMed ID: 11701699
    [Abstract] [Full Text] [Related]

  • 15. Role of opioid antagonists in the treatment of women with glucoregulation abnormalities.
    Guido M, Romualdi D, Lanzone A.
    Curr Pharm Des; 2006 Nov; 12(8):1001-12. PubMed ID: 16533167
    [Abstract] [Full Text] [Related]

  • 16. Growth hormone in obesity.
    Scacchi M, Pincelli AI, Cavagnini F.
    Int J Obes Relat Metab Disord; 1999 Mar; 23(3):260-71. PubMed ID: 10193871
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.